Key facts
- It has raised $430K; the latest was Early Stage VC ($430K) in Feb 2026.
- Notable investors include Beijing Chuangke Zhisheng.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Jijun Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Jijun Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jijun Bio
Manufacturer of biotechnology products designed to advance health and life sciences. The company operates in the biotechnology and pharmaceutical industry, focusing on research, development, production, and commercialization of biological technologies, with a value proposition centered on innovation, scientific expertise, and delivering efficient solutions that support healthcare and industrial applications.
- Sector
- Healthcare
- HQ
- Wenzhou, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Jijun Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jijun Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jijun Bio in its N-PORT filings yet. We sweep new filings monthly.